Faron Pharma’s latest results from the BEXMAB trial in aggressive myeloid leukaemias (a rare blood cancer) showed more promising results, according to broker Peel Hunt.
Responses were noted in the two groups where previous treatments had failed, with seven out of ten of these seeing a complete response/marrow response.
Peel Hunt added the treatment, bexmarilimab, presents a very promising approach to igniting immunity, allowing a patient’s immune system to overcome resistance from the ‘tumour microenvironment’ or to supplement/enhance existing immuno-oncology approaches.
Faron added that it is well positioned to advance to the Phase 2 part of the BEXMAB study and actively pursue further regulatory interactions to navigate and refine the pivotal pathway for BLA filing.
Peel Hunt has a target price of 417p.